Skip to main content

Advertisement

Table 2 PTEN status of various cancer types as adapted from reference [133]

From: PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy

Cancer type PTEN status References
Head and neck cancer - Decreased PTEN expression in 30% of patients [154]
Glioblastoma - Loss of heterozygosity of PTEN in 60%–80% of patients [155]
- PTEN mutations in up to 40% of patients
Breast cancer - PTEN mutations in 3% of patients [156, 157]
- Loss of PTEN protein in 30% of patients
Ovarian cancer - Loss of heterozygosity of PTEN in 45% of endometrioid carcinoma of the ovary [158]
Non-small cell lung cancers - Loss of PTEN protein expression in 75% of patients [159]
Endometrial cancer - Mutation or reduction of heterozygosity in 55% of patients [160]
Colorectal cancer - Loss of PTEN protein expression in 20%-40% of patients [161]
Prostate cancer - PTEN mutations in 15% of primary tumours, 20% of localised tumours and 50% of hormone-refractory cancer patients [162]